Results

Zacks Small Cap Research – CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more

Mixed economic results and growing political conflict – Hungary’s 20 years of EU membership – Go Health Pro

by
Mixed economic results and growing political conflict – Hungary’s 20 years of EU membership – Go Health Pro

Hungary is often portrayed as a problem case for European integration due to frequent clashes between Viktor Orbán’s government and the EU’s institutions. Yet as András Bíró-Nagy and Gergő Medve-Bálint explain, the country’s 20 years in the EU have also seen a relatively high level of compliance with EU policies and strong support for membership … Read more

Hidden content tricks ChatGPT into rewriting search results, Guardian shows – Go Health Pro

by
Hidden content tricks ChatGPT into rewriting search results, Guardian shows – Go Health Pro

In October, OpenAI’s ChatGPT Search became available for ChatGPT Plus users. Last week, it became available to all users and was added to search in Voice Mode. And, of course, it isn’t without its flaws. The Guardian asked ChatGPT to summarize webpages that contain hidden content and, it turns out, hidden content can manipulate the … Read more

Zacks Small Cap Research – NRXBF: Promising Company Releases Results – Go Health Pro

by

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a potential market for ExoPTEN of approximately 50,000 new cases globally per year—an enormous market potential with patients eager to … Read more

Zacks Small Cap Research – EVAX Racks up Positive Test Results – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company’s AI models, novel targets within … Read more

x